Payment overview · 2025
General Payments
$17,965.88
29 reported records · 3 companies
Healthcare provider profile · identity verified
Bernard Gottschalk, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Addiction Medicine · WILMINGTON, NC · NPI 1629298872
Verified facts
What the public records show
CMS Open Payments records show Bernard Gottschalk, MD received $17,965.88 in general payments during 2025 across 29 reported records.
Indivior Inc. accounted for 66.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Sublocade, Vivitrol.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Vivitrol by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $11,851.65 | 66.0% | 22 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $6,079.95 | 33.8% | 5 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $34.28 | 0.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,604.50 | 6 |
| Travel and Lodging | $1,685.23 | 5 |
| Consulting Fee | $900.00 | 1 |
| Food and Beverage | $776.15 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $11,851.65 | 22 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $6,079.95 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $34.28 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 94 | exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 204 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
204 | 180 |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
94 | 82 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 230 | 148 |
| Quetiapine Fumarate | Quetiapine Fumarate | 220 | 112 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 217 | 155 |
| Vivitrol | Naltrexone Microspheres | 204 | 180 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 104 |
| Mirtazapine | Mirtazapine | 132 | 105 |
| Methocarbamol | Methocarbamol | 129 | 89 |
| Doxepin Hcl | Doxepin Hcl | 122 | 87 |
| Prednisone | Prednisone | 118 | 97 |
| Lisinopril | Lisinopril | 108 | 77 |
| Omeprazole | Omeprazole | 108 | 74 |
| Sublocade | Buprenorphine | 94 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 90 | 73 |
| Lucemyra | Lofexidine Hcl | 90 | 76 |
| Furosemide | Furosemide | 86 | 68 |
| Propranolol Hcl | Propranolol Hcl | 85 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 49 |
| Potassium Chloride | Potassium Chloride | 72 | 57 |
| Levetiracetam | Levetiracetam | 71 | 55 |
| Buspirone Hcl | Buspirone Hcl | 69 | 43 |
| Atomoxetine Hcl | Atomoxetine Hcl | 68 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 68 | 55 |
| Sertraline Hcl | Sertraline Hcl | 68 | 51 |
| Metformin Hcl | Metformin Hcl | 67 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 45 |
| Aripiprazole | Aripiprazole | 56 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 40 |
| Prazosin Hcl | Prazosin Hcl | 54 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 46 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 53 | 46 |
| Lofexidine Hcl | Lofexidine Hcl | 47 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 27 |
| Losartan Potassium | Losartan Potassium | 44 | 33 |
| Naltrexone Hcl | Naltrexone Hcl | 44 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | 28 |
| Meloxicam | Meloxicam | 41 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Ziprasidone Hcl | Ziprasidone Hcl | 32 | 24 |
| Lamotrigine | Lamotrigine | 31 | 19 |
| Azithromycin | Azithromycin | 30 | 28 |
| Bupropion Xl | Bupropion Hcl | 30 | 28 |
| Olanzapine | Olanzapine | 30 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 26 |
| Topiramate | Topiramate | 25 | 19 |
| Vraylar | Cariprazine Hcl | 25 | 19 |
| Eliquis | Apixaban | 24 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 23 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | 16 |
| Carvedilol | Carvedilol | 19 | 16 |
| Clonidine Hcl | Clonidine Hcl | 19 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 19 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Jardiance | Empagliflozin | 19 | 13 |
| Risperidone | Risperidone | 19 | 14 |
| Enulose | Lactulose | 18 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | 14 |
| Fluconazole | Fluconazole | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 16 |
| Lurasidone Hcl | Lurasidone Hcl | 16 | 13 |
| Celecoxib | Celecoxib | 15 | 11 |
| Cephalexin | Cephalexin | 15 | 15 |
| Lidocaine | Lidocaine | 15 | 15 |
| Guanfacine Hcl | Guanfacine Hcl | 14 | 12 |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Famotidine | Famotidine | 12 | 11 |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,965.88 · 29 records | Indivior Inc. | BRIXADI, SUBLOCADE, VIVITROL | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Sublocade play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error